UK life sciences company, SkinBioTherapeutics, announces end of year results following news of first commercial deal

UK life sciences company focused on skin health, SkinBioTherapeutics, has announced its full year results and released details of its strengthened board and management team following the appointment of Stuart Ashman CEO.

These announcements follow a positive year that has seen SkinBioTherapeutics complete its first human cosmetic study, and sign its first commercial agreement with Croda International Plc. Croda is an international speciality chemical company supplying some of the world’s biggest brands and will be exploring the design and manufacture of a new active cosmetic ingredient based on SkinBio Therapeutics’ pioneering SkinBiotix™ skin microbiome technology.

Powered by the discoveries about lysates and the skin microbiome made at the University of Manchester by Professor Cath O’Neill and Professor Andrew McBain, SkinBioTherapeutics is developing a range of scientifically-validated treatments derived from probiotic bacteria. SkinBioTherapeutics’ patented skin microbiome technology, SkinBiotix®, applies lysates derived from probiotic bacteria to the skin, and has been shown to improve the skin barrier, protect skin from infection and help skin to repair.

The use of bacteria in beauty and topical probiotic products are a growing global trend and there is a number of exciting developments in this space with many significant players looking at the role the skin microbiome can play. Reviews in the International Journal of Women’s Dermatology and the Journal of Drugs in Dermatology confirm this, suggesting topical probiotics help hydrate, protect and improve the acid mantel.

Stuart Ashman, CEO, SkinBioTherapeutics said: “Whilst there is significant interest in this space, we have always been keen to establish a solid scientific foundation and evidence the benefits our SkinBiotix® technology and the positive effects of it on the barrier function of the skin. The research conducted by our CSO Dr Cath O’Neill to date, has put us in a very strong position to develop a cosmetic ingredient with the potential to really exploit the full potential of the skin microbiome. We now feel confident driving the commercial conversations forwards and anticipate that Croda is the first of many announcements to come.”

 About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by Dr Catherine O’Neill and Professor Andrew McBain.

The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotherapeutics.com.